LRG1 predicts kidney disease progression in type 2 diabetes patients
Singapore: Diabetes is the leading cause of end-stage kidney disease (ESKD) in many countries (1). The pathophysiological mechanisms underlying the pathogenesis and progression of diabetic kidney disease (DKD) are only partially understood.
According to research published in the Diabetes care Journal, Urine leucine-rich-alpha-2 glycoprotein 1 (LRG1) is a novel protein involved in the pathophysiology of progressive kidney disease with type 2 diabetes (T2D).
The team of researchers studied the association between LRG1 levels and end-stage kidney disease (ESKD).
In animal models, LRG1 is identified as an amplifier of transforming growth factor-β (TGF-β)–induced kidney fibrosis.
The researcher's team, led by Jian-Jun Liu from the Khoo Teck Puat Hospital studied the role of LRG1 in type 2 diabetes individuals regarding its association with the risk of progression to end-stage kidney disease (ESKD).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.